Timeline Mitopure (Urolithin A) review: is it worth it?

What is Mitopure and who makes it?

Mitopure is the flagship product of Timeline (Timeline Nutrition), the consumer brand of the Swiss life-science company Amazentis SA, an EPFL (École Polytechnique Fédérale de Lausanne) spinout. Amazentis is the original research engine behind most of the foundational science on Urolithin A and mitophagy, including the influential preclinical work published in *Nature Medicine* in 2016 (Ryu et al.). That academic lineage is unusual for a supplement and is central to Timeline's positioning.

The single active ingredient is Urolithin A (UA). UA is not something Timeline invented — it is a metabolite your body can make when gut bacteria break down ellagitannins, compounds found in pomegranate, raspberries, strawberries, and walnuts. The catch is that this conversion depends on having the right gut microbes: studies suggest only roughly 30–40% of people harbor bacteria that produce meaningful UA from food, and amounts even in producers are small and inconsistent. Mitopure sidesteps that lottery by delivering a standardized, synthesized dose of the finished metabolite directly.

One framing point that matters: Mitopure is a dietary supplement, not an FDA-approved drug. It is not approved to treat, cure, or prevent any disease, and the FDA does not vet supplements for efficacy before sale. What Mitopure does have is a GRAS (Generally Recognized As Safe) "no questions" letter from the FDA (GRAS Notice GRN 791) and NSF certification — but GRAS speaks to *safety as a food ingredient*, not to any anti-aging or performance benefit.

How does Urolithin A work?

The proposed mechanism is mitophagy — the cellular housekeeping process that identifies damaged, inefficient mitochondria and recycles them. Mitochondria are the cell's energy plants, and they accumulate damage with age. The thesis behind UA is that by stimulating mitophagy, cells clear out dysfunctional mitochondria and make room for healthy ones, improving overall mitochondrial quality and energy output — particularly in high-demand tissues like skeletal muscle.

In animal models, this story is fairly strong: in aged mice and in *C. elegans* worms, UA improved muscle function and endurance and extended lifespan in the worm model (*Nature Medicine* 2016, Ryu et al.). Mechanistically, UA is also one of the few candidate mitophagy inducers that is orally bioavailable and reaches measurable blood levels in humans.

The crucial caveat — true of the entire longevity-supplement category — is the gap between mechanism and outcome. Activating mitophagy and lowering certain biomarkers are *intermediate* changes. Whether that reliably translates into a person feeling stronger, performing better, or aging more slowly is the open question, and mechanism alone cannot answer it. Below is what the human trials actually found.

Does Mitopure actually work? What the human trials show

UA is genuinely better-studied in humans than most supplements — Timeline cites a portfolio of clinical work. But the two pivotal randomized controlled trials are more nuanced than the marketing implies, and both missed their pre-specified primary endpoints.

The ATLAS trial (middle-aged adults)

Published in *Cell Reports Medicine* in 2022 (Singh et al.; DOI 10.1016/j.xcrm.2022.100633; NCT03464500), ATLAS was a randomized, double-blind, placebo-controlled trial in 88 untrained, overweight, middle-aged adults randomized to placebo, 500 mg, or 1,000 mg of UA daily for 4 months.

• Primary endpoint (peak power output during cycling): not met — no statistically significant improvement over placebo.
• Reported a roughly 12% improvement in muscle strength (a secondary measure).
• Showed clinically meaningful gains in aerobic endurance (peak VO₂) and the 6-minute walk test.
• Plasma acylcarnitines and C-reactive protein (CRP) were significantly lower, consistent with improved mitochondrial efficiency and reduced inflammation.

The ENERGIZE trial (older adults)

Published in *JAMA Network Open* in 2022 (Liu et al.; PMID 35050355), ENERGIZE enrolled 66 older adults (mean age ~72, 76% women, and all of them White — a notably non-diverse sample) randomized to 1,000 mg UA daily or placebo for 4 months at the University of Washington.

• Co-primary endpoints (6-minute walk distance and maximal ATP production in muscle): not met — neither reached statistical significance versus placebo. (The UA group walked further, +60.8 m vs +42.5 m, but the between-group difference was not significant.)
• Muscle endurance — a secondary outcome — improved significantly at 2 months in both a hand muscle and a leg muscle.
• Biomarkers again moved favorably: acylcarnitines, several ceramides, and CRP decreased in the UA group.

How to read this honestly

The consistent pattern across both trials is real but limited: UA reliably shifts mitochondrial and inflammatory biomarkers in a favorable direction and shows signals on muscle endurance, but it has not yet hit its headline functional endpoints (peak power, ATP production, walk distance). A 2025 systematic review of UA's effects on muscle strength, mass, and performance (medRxiv preprint, DOI 10.1101/2025.07.10.25331277, not yet peer-reviewed) reflects this mixed picture, concluding there is currently "insufficient evidence" to support UA for improving muscle function in any population while encouraging larger trials. None of this is fraudulent or fringe; it is simply early. The fair verdict is "biologically plausible and better-evidenced than its rivals, but not proven to deliver the outcomes most buyers want."

Who is Mitopure best for — and who should skip it?

Reasonable candidates:

• Adults 40+ noticing declines in stamina or muscle endurance who want an evidence-informed (not evidence-*proven*) mitochondrial-support option and can afford an open-ended monthly cost.
• People who already know or suspect they are not UA "producers" (most people aren't) and won't get UA from diet alone.
• Those drawn to a single, well-characterized, third-party-certified ingredient rather than a proprietary blend.

Who should skip it:

• Anyone expecting a noticeable strength, energy, or "anti-aging" effect. The trials do not support that promise, and 4 months is the minimum window in which any measurable change appeared.
• Pregnant or breastfeeding people, and children — not studied; no safety basis.
• People on a tight budget — at $90–$125/month with no guaranteed benefit, the opportunity cost is high relative to free interventions (resistance training, protein intake, sleep) that have far stronger evidence for the same goals.
• Anyone with a serious medical condition or on prescription medication should clear it with a clinician first.

Side effects and safety

UA's safety profile is one of its genuine strengths. Across the ATLAS and ENERGIZE trials, no serious treatment-related adverse events were reported, compliance was high (96–97% in ENERGIZE), and doses up to 1,000 mg/day were well tolerated for 4 months. The FDA GRAS notice (GRN 791) reflects an absence of safety objections for the ingredient.

Honest limitations on safety: the human safety record is short-term (months, not years) and based on small populations that were not very diverse — ENERGIZE, for instance, was predominantly White and female. There is no long-term human safety data, no data in pregnancy or pediatrics, and limited information on interactions with medications. Mild, transient digestive complaints are the most commonly reported issues anecdotally. "Well tolerated in trials" is accurate; "proven safe for years of daily use" is not yet established.

How to take it (dose and timing)

Timeline's standard dose is 500 mg of Mitopure per day, delivered as:

• 2 vegan softgels daily, or
• 1 powder stickpack daily (mixed into a drink), or
• 2 gummies daily.

Some users — and Timeline's own guidance — note that 1,000 mg/day was the dose used in ENERGIZE and the higher arm of ATLAS, and Timeline advises not exceeding 1,000 mg/day. Timeline recommends taking it for a minimum of 4 months, which aligns with the trial timelines — there is no evidence of meaningful effects on shorter horizons. There is no strong evidence favoring a specific time of day; consistency matters more than timing, and taking it with food is reasonable.

Cost and value

Mitopure is expensive for a single-ingredient supplement. A one-month supply (60 softgels, the 500 mg/day dose) runs roughly $90–$125 depending on format and whether you subscribe, on Timeline's site and Amazon. Doubling to the 1,000 mg trial dose roughly doubles that cost — meaning the dose with the most human data can approach $180–$250/month.

Put plainly: you are paying a premium for the only NSF-certified, FDA-GRAS, clinically studied UA ingredient, backed by the company that funded the foundational research. Against that, the evidence shows missed primary endpoints and modest, biomarker-level benefits. For value-conscious buyers, that is a hard sell. For someone who specifically wants the most-studied UA on the market and treats it as an experiment, the quality and purity justification is at least coherent.

How does it compare to alternatives?

• Pomegranate juice or extract: The "natural" route. Cheaper, but only delivers UA if you have the right gut bacteria, and even then in far smaller, unstandardized amounts. Two Mitopure softgels are marketed as delivering several times more UA than a glass of pomegranate juice. For reliable UA exposure, whole-food sources are unreliable.
• Other Urolithin A supplements (e.g., generic UA capsules on Amazon): Often cheaper, but most are not clinically tested, NSF-certified, or backed by published trials — and purity/dose accuracy is unverified. Timeline has publicly flagged quality concerns about competing UA products. Mitopure's edge here is verification, not a different molecule.
• NAD+ precursors (NR/NMN, e.g., Elysium Basis, Tru Niagen): A different longevity thesis — boosting NAD+ rather than recycling mitochondria. Like UA, these reliably move a biomarker (blood NAD+) but lack proof of downstream health or lifespan benefits in humans. Choosing between them is choosing between two unproven mechanisms.
• The strongest "alternative" of all — exercise: Resistance training and aerobic exercise are themselves potent, free mitophagy and mitochondrial-biogenesis stimuli, with overwhelming evidence for the exact outcomes (strength, endurance, healthy aging) UA targets. Any honest comparison has to note that the best-proven intervention in this space costs nothing.

The bottom line

Mitopure is, by the standards of the supplement aisle, unusually legitimate: a single, well-characterized, FDA-GRAS, NSF-certified ingredient from the company that pioneered the underlying science, with two published randomized controlled trials and a clean short-term safety record. That places it well above the typical "longevity" product.

But legitimacy is not the same as proven benefit. Both pivotal trials missed their primary endpoints, and the wins are real-but-modest, biomarker-and-endurance signals rather than clear gains in strength, energy, or aging. At $90–$250 a month — and requiring at least 4 months to see anything — Mitopure is best understood as an early-stage, scientifically interesting bet, not a sure thing. If you have the budget, want the most-studied UA available, and treat it as a multi-month experiment alongside (never instead of) exercise and protein, it is a defensible choice. If you are expecting to feel a difference or are hoping to slow aging, the current evidence does not justify the price.